Janssen’s Zytiga has been rejected by NICE for early treatment of aggressive prostate cancer

Experts state that it is looking highly unlikely that Janssen’s Zytiga plus androgen deprivation therapy (ADT) and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.   NICE have published draft guidelines rejecting the therapy in this setting, after concluding that the company’s economic

Continue Reading

MSD receive FDA fast track review for Keytuda to treat cervical cancer

US regulators will conduct a priority review of MSD’s Keytruda to treat patients with advanced cervical cancer. The company is seeking approval for the drug’s use in patients with cervical cancer who experience disease progression during or post chemotherapy. The FDA’s decision marks the first filing acceptance and priority review issued for an anti-PD-1 therapy

Continue Reading